Upstream Bio UPB
NASDAQ UPB
$3.20 -0.18 (-5.33%)
At close: Nov 11, 2026 · 4:00 PM EST

Upstream Bio (UPB) Other Accumulated Expenses (2024 - 2025)

Updated

Upstream Bio (UPB) posted Other Accumulated Expenses of $55,000 for Q3 2025, down 53.4% from $118,000 a year earlier.

Analysis

Upstream Bio (UPB) Other Accumulated Expenses (2024 - 2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Upstream Bio 185.26 Mn -919.50 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 55,000.00
Sep 30, 2024 118,000.00
API Access

Upstream Bio Other Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=UPB&period=max&api_key=YOUR_API_KEY